600867 通化东宝
已收盘 08-19 15:00:00
资讯
新帖
简况
每周股票复盘:通化东宝(600867)东宝集团累计质押5.82亿股
证券之星 · 08-16
每周股票复盘:通化东宝(600867)东宝集团累计质押5.82亿股
股市必读:通化东宝新发布《通化东宝关于控股股东股份解押及再质押公告》
证券之星 · 08-13
股市必读:通化东宝新发布《通化东宝关于控股股东股份解押及再质押公告》
通化东宝:胰岛素西林瓶生产线项目目前处于建设推进阶段
证券之星 · 08-12
通化东宝:胰岛素西林瓶生产线项目目前处于建设推进阶段
通化东宝(600867)披露参与认购特宝生物可转债结果,8月11日股价上涨0.84%
证券之星 · 08-11
通化东宝(600867)披露参与认购特宝生物可转债结果,8月11日股价上涨0.84%
通化东宝(600867)股东东宝实业集团股份有限公司质押1900万股,占总股本0.97%
证券之星 · 08-11
通化东宝(600867)股东东宝实业集团股份有限公司质押1900万股,占总股本0.97%
通化东宝:甘精胰岛素BLA已正式向美国 FDA 递交
证券之星 · 08-11
通化东宝:甘精胰岛素BLA已正式向美国 FDA 递交
通化东宝:1.62亿元认购特宝生物可转债获配售将上市
格隆汇 · 08-11
通化东宝:1.62亿元认购特宝生物可转债获配售将上市
股市必读:通化东宝(600867)8月6日董秘有最新回复
证券之星 · 08-07
股市必读:通化东宝(600867)8月6日董秘有最新回复
通化东宝:2026年第一季度加权平均净资产收益率为1.77%
证券之星 · 08-06
通化东宝:2026年第一季度加权平均净资产收益率为1.77%
通化东宝:公司将继续通过提升经营质量、推进产品放量和创新研发,努力提升长期回报能力
证券之星 · 08-06
通化东宝:公司将继续通过提升经营质量、推进产品放量和创新研发,努力提升长期回报能力
每周股票复盘:通化东宝(600867)门冬胰岛素获FDA上市批准
证券之星 · 08-02
每周股票复盘:通化东宝(600867)门冬胰岛素获FDA上市批准
通化东宝(600867)披露控股股东股份解押及再质押公告,7月28日股价上涨2.48%
证券之星 · 07-28
通化东宝(600867)披露控股股东股份解押及再质押公告,7月28日股价上涨2.48%
通化东宝最新公告:门冬胰岛素注射液获美国FDA上市批准
证券之星 · 07-27
通化东宝最新公告:门冬胰岛素注射液获美国FDA上市批准
通化东宝(600867.SH)拟认购特宝生物可转债不超1.62亿元
智通财经 · 07-27
通化东宝(600867.SH)拟认购特宝生物可转债不超1.62亿元
健友股份:与通化东宝战略合作核心聚焦于美国市场
证券之星 · 07-10
健友股份:与通化东宝战略合作核心聚焦于美国市场
6月29日通化东宝涨9.96%,南华丰汇混合A基金重仓该股
证券之星 · 06-29
6月29日通化东宝涨9.96%,南华丰汇混合A基金重仓该股
通化东宝涨9.96%,交银国际证券一个月前给出“买入”评级,目标价11.20元
证券之星 · 06-29
通化东宝涨9.96%,交银国际证券一个月前给出“买入”评级,目标价11.20元
异动快报:通化东宝(600867)6月29日13点21分触及涨停板
证券之星 · 06-29
异动快报:通化东宝(600867)6月29日13点21分触及涨停板
6月23日通化东宝涨6.06%,南华丰汇混合A基金重仓该股
证券之星 · 06-23
6月23日通化东宝涨6.06%,南华丰汇混合A基金重仓该股
通化东宝涨6.06%,交银国际证券一个月前给出“买入”评级,目标价11.20元
证券之星 · 06-23
通化东宝涨6.06%,交银国际证券一个月前给出“买入”评级,目标价11.20元
加载更多
公司概况
公司名称:
通化东宝药业股份有限公司
所属行业:
医药制造业
上市日期:
1994-08-24
主营业务:
通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂、甘精胰岛素原料药、甘精胰岛素注射液、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素、利拉鲁肽注射液、恩格列净片、镇脑宁胶囊、糖尿病相关的医疗器械。公司拥有国家级企业技术中心、国家GMP和欧盟GMP认证的生产车间。被国家认定为高新技术企业、国家技术创新示范企业、ISO14001环境体系认证企业。
发行价格:
6.50
{"stockData":{"symbol":"600867","market":"SH","secType":"STK","nameCN":"通化东宝","latestPrice":8.24,"timestamp":1787122801000,"preClose":8.36,"halted":0,"volume":24347427,"delay":0,"changeRate":-0.0144,"floatShares":1959000000,"shares":1959000000,"eps":0.6315,"marketStatus":"已收盘","change":-0.12,"latestTime":"08-19 15:00:00","open":8.35,"high":8.42,"low":8.19,"amount":201000000,"amplitude":0.0275,"askPrice":8.24,"askSize":202,"bidPrice":8.23,"bidSize":921,"shortable":0,"etf":0,"ttmEps":0.6315,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":5,"adr":0,"adjPreClose":8.36,"symbolType":"stock","openAndCloseTimeList":[[1787103000000,1787110200000],[1787115600000,1787122800000]],"highLimit":9.2,"lowLimit":7.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1958542829,"isCdr":false,"pbRate":2.23,"roa":"--","peRate":13.048298,"roe":"1.77%","epsLYR":0.62,"committee":0.11157,"marketValue":16138000000,"turnoverRate":0.0124,"status":1,"floatMarketCap":16138000000},"requestUrl":"/m/hq/s/600867","defaultTab":"news","newsList":[{"id":"2659175404","title":"每周股票复盘:通化东宝(600867)东宝集团累计质押5.82亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175404?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:57","pubTimestamp":1786816630,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,通化东宝报收于8.57元,较上周的8.42元上涨1.78%。本周,通化东宝8月11日盘中最高价报8.82元。本次解押及再质押后,东宝集团累计质押股份581,939,472股,占其所持公司股份的93.94%,占公司总股本的29.71%。通化东宝药业股份有限公司控股股东东宝集团于2026年8月11日解除质押32,000,000股,并同日将相同数量股份重新质押给交通银行股份有限公司通化分行,用于补充流动资金。东宝集团及其一致行动人合计质押股份占其所持股份总额的90.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0196","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659390117","title":"股市必读:通化东宝新发布《通化东宝关于控股股东股份解押及再质押公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659390117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659390117?lang=zh_cn&edition=full","pubTime":"2026-08-13 01:05","pubTimestamp":1786554315,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,通化东宝报收于8.39元,下跌0.71%,换手率1.48%,成交量28.92万手,成交额2.45亿元。公司公告汇总:控股股东东宝集团于8月10日、8月11日分别完成两笔各1900万股、3200万股的股份解押及再质押,累计质押股份数维持581,939,472股,占其所持股份93.94%、占公司总股本29.71%。公司公告汇总:通化东宝以16,204.20万元认购特宝生物可转债1,620,420张,该债券将于8月13日在上交所上市,公司承诺六个月内不减持。公告明确本次质押不影响公司生产经营和控制权稳定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300000892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0196","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658922954","title":"通化东宝:胰岛素西林瓶生产线项目目前处于建设推进阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2658922954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658922954?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:33","pubTimestamp":1786520001,"startTime":"0","endTime":"0","summary":"证券之星消息,通化东宝(600867)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好!看到“通化县发布”8月8日新闻,提及贵司“西林瓶项目”建设,我想了解项目建设缘由、建设规模、建设进度等方面的情况,希望回复,谢谢!通化东宝回复:感谢您对公司的关注。公司胰岛素西林瓶生产线项目目前处于建设推进阶段,设计产能为 4,000 万支。该项目主要用于扩大公司制剂灌装能力,匹配快速增长的海外出口订单增量需求,是公司国际化产能布局的重要组成部分。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200021013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916091","title":"通化东宝(600867)披露参与认购特宝生物可转债结果,8月11日股价上涨0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916091","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916091?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:20","pubTimestamp":1786458029,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘,通化东宝报收于8.45元,较前一交易日上涨0.84%,最新总市值为165.5亿元。该股当日开盘8.37元,最高8.82元,最低8.36元,成交额达4.22亿元,换手率为2.52%。近日,通化东宝发布《关于行使优先配售权参与认购厦门特宝生物工程股份有限公司向不特定对象发行可转换公司债券的结果公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","688278","600867","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673991","title":"通化东宝(600867)股东东宝实业集团股份有限公司质押1900万股,占总股本0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673991","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673991?lang=zh_cn&edition=full","pubTime":"2026-08-11 18:22","pubTimestamp":1786443748,"startTime":"0","endTime":"0","summary":"证券之星消息,通化东宝8月11日公开信息显示,股东东宝实业集团股份有限公司向中国农业银行股份有限公司通化县支行合计质押1900.0万股,占总股本0.97%。质押详情见下表:截止本公告日,股东东宝实业集团股份有限公司已累计质押股份5.82亿股,占其持股总数的93.94%。通化东宝主营业务:药品研发、生产和销售,主要业务涵盖生物制品、中成药、化学药,治疗领域以糖尿病及内分泌、心脑血管为主。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100031710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0239","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995604","title":"通化东宝:甘精胰岛素BLA已正式向美国 FDA 递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995604","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658995604?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:54","pubTimestamp":1786438457,"startTime":"0","endTime":"0","summary":"证券之星消息,通化东宝(600867)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好!最近看到健友股份美国子公司发布的消息,贵司甘精胰岛素BLA已经递交FDA评审,烦介绍详细情况。谢谢!通化东宝回复:感谢您对公司的关注。甘精胰岛素BLA已正式向美国 FDA 递交。甘精胰岛素注射液系公司与健友股份合作开发的三款美国市场胰岛素产品之一(门冬、甘精、赖脯),其中门冬胰岛素已获得美国 FDA 批准上市,是首个获美国 FDA 上市许可的国产门冬胰岛素注射液。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100026607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658960092","title":"通化东宝:1.62亿元认购特宝生物可转债获配售将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2658960092","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658960092?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:40","pubTimestamp":1786434059,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0196","688278","BK0239","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651005","title":"股市必读:通化东宝(600867)8月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657651005?lang=zh_cn&edition=full","pubTime":"2026-08-07 02:32","pubTimestamp":1786041133,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,通化东宝报收于8.11元,下跌1.82%,换手率1.21%,成交量23.62万手,成交额1.92亿元。董秘最新回复投资者: 董秘你好!后续如有新的回购注销计划,公司将严格按照规定履行信息披露义务。同期,公司营业收入同比增长 14.76%,归属于上市公司股东的净利润同比增长 16.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700002194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689534","title":"通化东宝:2026年第一季度加权平均净资产收益率为1.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657689534?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:03","pubTimestamp":1786006993,"startTime":"0","endTime":"0","summary":"证券之星消息,通化东宝08月06日在投资者关系平台上答复投资者关心的问题。请问,为啥今年一季度,贵公司净资产收益率 大幅下降?公司2026年第一季度加权平均净资产收益率为 1.77%,上年同期为 1.70%,同比增加 0.07 个百分点,您提到的净资产收益率下降可能存在误解,实际实现同比提升。同期,公司营业收入同比增长 14.76%,归属于上市公司股东的净利润同比增长 16.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600027864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","600867","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689551","title":"通化东宝:公司将继续通过提升经营质量、推进产品放量和创新研发,努力提升长期回报能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657689551?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:03","pubTimestamp":1786006987,"startTime":"0","endTime":"0","summary":"证券之星消息,通化东宝(600867)08月06日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司股票价格跌跌不休,市值不断缩水,贵公司近期有没有股票回购注销计划维护市值稳定通化东宝回复:感谢您对公司的关注。公司始终将股东回报置于重要位置,并持续通过股份回购、员工持股计划/股权激励、现金分红等多种方式积极回报投资者与维护公司价值。公司将继续通过提升经营质量、推进产品放量和创新研发,努力提升长期回报能力。后续如有新的回购注销计划,公司将严格按照规定履行信息披露义务。我们会将您的建议转达公司管理层。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600027860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656031969","title":"每周股票复盘:通化东宝(600867)门冬胰岛素获FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656031969","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656031969?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:19","pubTimestamp":1785611949,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,通化东宝报收于8.37元,较上周的7.79元上涨7.45%。本周,通化东宝7月29日盘中最高价报8.47元。本周关注点公司公告汇总:门冬胰岛素注射液获美国FDA上市批准。该药品名为Garzulys,适用于改善成人及儿科糖尿病患者的血糖控制。东宝集团及其一致行动人合计持有公司股份641,362,975股,占公司总股本的32.75%,累计质押股份占其所持股份的90.73%。公告披露了东宝集团财务状况、偿债能力及质押风险应对措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0188","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654888730","title":"通化东宝(600867)披露控股股东股份解押及再质押公告,7月28日股价上涨2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654888730","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654888730?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:17","pubTimestamp":1785248236,"startTime":"0","endTime":"0","summary":"近日,通化东宝药业股份有限公司发布《关于控股股东股份解押及再质押公告》。公告显示,公司控股股东东宝集团于2026年7月27日解除质押给中国建设银行股份有限公司通化分行的33,000,000股股份,并同日将相同数量股份重新质押给该行,用于偿还债务。本次解押及再质押后,东宝集团累计质押股份581,939,472股,占其所持公司股份的93.94%,占公司总股本的29.71%。公告披露了东宝集团财务状况、偿债能力及质押风险应对措施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","600867","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654168600","title":"通化东宝最新公告:门冬胰岛素注射液获美国FDA上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654168600","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654168600?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:24","pubTimestamp":1785144259,"startTime":"0","endTime":"0","summary":"通化东宝(600867.SH)公告称,公司与健友股份合作开发的门冬胰岛素注射液正式获得美国食品药品监督管理局(FDA)上市批准,用于改善成人及儿科糖尿病患者的血糖控制。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700022317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600867","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654183470","title":"通化东宝(600867.SH)拟认购特宝生物可转债不超1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654183470","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654183470?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:01","pubTimestamp":1785139282,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 通化东宝(600867.SH)发布公告,公司参股公司厦门特宝生物工程股份有限公司(证券简称:特宝生物,证券代码:688278)向不特定对象发行可转换公司债券,募集资金总额不超过人民币15.33亿元。公司计划行使优先配售权参与认购特宝生物可转债。本次计划参与认购特宝生物可转债的投资本金不超过1.62亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SABA","688278","BK0188","BK0196","FCEF","BK0239","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650186077","title":"健友股份:与通化东宝战略合作核心聚焦于美国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2650186077","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650186077?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:33","pubTimestamp":1783676003,"startTime":"0","endTime":"0","summary":"证券之星消息,健友股份07月10日在投资者关系平台上答复投资者关心的问题。年报显示,门冬胰岛素正在向欧洲和美国获批中,跟通化东宝的合作未来也包含欧洲市场吗?目前公司与通化东宝的战略合作核心聚焦于美国市场。公司已获得包括门冬胰岛素等相关产品在美国的独家商业化权益,合作协议范围尚未包含欧洲市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0188","BK0196","BK0046","BK0239","BK0186","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324496","title":"6月29日通化东宝涨9.96%,南华丰汇混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647324496?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:30","pubTimestamp":1782721851,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日通化东宝涨9.96%,收盘报8.17元,换手率2.97%,成交量58.21万手,成交额4.58亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为南华基金的南华丰汇混合A。南华丰汇混合A目前规模为9.67亿元,最新净值1.864,较上一交易日下跌2.6%,近一年上涨20.91%。南华丰汇混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","600867","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324457","title":"通化东宝涨9.96%,交银国际证券一个月前给出“买入”评级,目标价11.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647324457?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:30","pubTimestamp":1782721840,"startTime":"0","endTime":"0","summary":"今日通化东宝(600867)涨9.96%,收盘报8.17元。2026年5月12日,交银国际证券研究员丁政宁,诸葛乐懿发布了对通化东宝的研报《三代胰岛素驱动业绩强势复苏,糖尿病产品矩阵快速丰富,维持买入》,该研报对通化东宝给出“买入”评级,认为其目标价为11.2元,现价距离目标价尚有37.09%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为49.76%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中信证券的甘坛焕。通化东宝(600867)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","600867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647323549","title":"异动快报:通化东宝(600867)6月29日13点21分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2647323549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647323549?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:31","pubTimestamp":1782711063,"startTime":"0","endTime":"0","summary":"证券之星6月29日盘中消息,13点21分通化东宝(600867)触及涨停板。其所属行业生物制品目前上涨。领涨股为三生国健。该股为减肥药,创新药,医药概念热股,当日减肥药概念上涨7.01%,创新药概念上涨6.89%,医药概念上涨4.94%。6月26日的资金流向数据方面,主力资金净流出2582.36万元,占总成交额14.01%,游资资金净流入112.07万元,占总成交额0.61%,散户资金净流入2470.28万元,占总成交额13.4%。近5日资金流向一览见下表:通化东宝主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900016389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","600867","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645812398","title":"6月23日通化东宝涨6.06%,南华丰汇混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645812398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645812398?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:45","pubTimestamp":1782204347,"startTime":"0","endTime":"0","summary":"证券之星消息,6月23日通化东宝涨6.06%,收盘报7.87元,换手率3.21%,成交量62.91万手,成交额4.95亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为南华基金的南华丰汇混合A。南华丰汇混合A目前规模为9.67亿元,最新净值1.9502,较上一交易日上涨1.08%,近一年上涨31.19%。南华丰汇混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","BK0196","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645588124","title":"通化东宝涨6.06%,交银国际证券一个月前给出“买入”评级,目标价11.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645588124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645588124?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:45","pubTimestamp":1782204336,"startTime":"0","endTime":"0","summary":"今日通化东宝(600867)涨6.06%,收盘报7.87元。2026年5月12日,交银国际证券研究员丁政宁,诸葛乐懿发布了对通化东宝的研报《三代胰岛素驱动业绩强势复苏,糖尿病产品矩阵快速丰富,维持买入》,该研报对通化东宝给出“买入”评级,认为其目标价为11.2元,现价距离目标价尚有42.31%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为49.76%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中信证券的甘坛焕。通化东宝(600867)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600867","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787127267142,"stockEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0437},{"period":"3month","weight":0.0109},{"period":"6month","weight":-0.0031},{"period":"1year","weight":0.035},{"period":"ytd","weight":0.0616}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0601},{"period":"3month","weight":-0.0413},{"period":"6month","weight":-0.0225},{"period":"1year","weight":0.0704},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化东宝药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"103178人(较上一季度增加20.31%)","perCapita":"18982股","listingDate":"1994-08-24","address":"吉林省通化市通化县东宝新村","registeredCapital":"195854万元","survey":" 通化东宝药业股份有限公司的主营业务是糖尿病及内分泌治疗领域生物制品、中成药、化学药等药品的研发、生产和销售。公司的主要产品是人胰岛素原料药、人胰岛素注射剂、甘精胰岛素原料药、甘精胰岛素注射液、门冬胰岛素原料药、门冬胰岛素注射液、预混型门冬胰岛素、利拉鲁肽注射液、恩格列净片、镇脑宁胶囊、糖尿病相关的医疗器械。公司拥有国家级企业技术中心、国家GMP和欧盟GMP认证的生产车间。被国家认定为高新技术企业、国家技术创新示范企业、ISO14001环境体系认证企业。","listedPrice":6.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化东宝,600867,通化东宝股票,通化东宝股票老虎,通化东宝股票老虎国际,通化东宝行情,通化东宝股票行情,通化东宝股价,通化东宝股市,通化东宝股票价格,通化东宝股票交易,通化东宝股票购买,通化东宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化东宝(600867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化东宝(600867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}